An international research team led by scientists from the University of Liège has discovered an interesting new therapeutic target for the treatment of melanoma resistant to targeted therapies.
2024
Uveal Melanoma Immunogenomic Score Shows Predictive Potential
Investigators examined 100 metastases and developed a Uveal Melanoma Immunogenomic Score to predict which patients will respond to immunotherapy.
Pembrolizumab/Vibostolimab Coformulation for Melanoma to be Discontinued
The phase 3 KeyVibe-010 study will discontinue the coformulation of pembrolizumab and vibostolimab treatment for high-risk melanoma due to futility.
Not all treatments created equal: Identifying barriers to immunotherapy for melanoma
Immunotherapy is an effective yet very expensive treatment for melanoma.